Arrowhead Pharmaceuticals Launches Phase 1/2a Trial of ARO-MAPT for Alzheimer’s Disease

Reuters

Dec 08, 2025

Arrowhead Pharmaceuticals Launches Phase 1/2a Trial of ARO-MAPT for Alzheimer's Disease

Arrowhead Pharmaceuticals Inc. announced the initiation of a Phase 1/2a clinical trial for ARO-MAPT, an investigational RNA interference (RNAi) therapeutic targeting tauopathies, including Alzheimer's disease. ARO-MAPT utilizes Arrowhead's proprietary Targeted RNAi Molecule (TRiM™) platform, designed for subcutaneous administration and systemic delivery to the central nervous system by crossing the blood-brain barrier. In preclinical studies presented at the RNA Leaders USA Congress 2025, ARO-MAPT demonstrated potent and sustained suppression of microtubule associated protein tau $(MAPT)$ mRNA and tau protein in non-human primates. The company indicates that these results may enable monthly or quarterly dosing with uniform CNS distribution. Presentation slides are available on the Arrowhead website.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Arrowhead Pharmaceuticals Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20251208566889) on December 08, 2025, and is solely responsible for the information contained therein.

At the request of the copyright holder, you need to log in to view this content

LOGIN / SIGN UP

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2589330083"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2589330083\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2589330083?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-12-08 20:30","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2589330083","market":"nz","top_or_hot":-1,"title":"Arrowhead Pharmaceuticals Launches Phase 1/2a Trial of ARO-MAPT for Alzheimer’s Disease","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Arrowhead Pharmaceuticals Launches Phase 1/2a Trial of ARO-MAPT for Alzheimer's Disease\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Arrowhead Pharmaceuticals Inc. announced the initiation of a Phase 1/2a clinical trial for ARO-MAPT, an investigational RNA interference (RNAi) therapeutic targeting tauopathies, including Alzheimer's disease. ARO-MAPT utilizes Arrowhead's proprietary Targeted RNAi Molecule (TRiM™) platform, designed for subcutaneous administration and systemic delivery to the central nervous system by crossing the blood-brain barrier. In preclinical studies presented at the RNA Leaders USA Congress 2025, ARO-MAPT demonstrated potent and sustained suppression of microtubule associated protein tau <a href=\"https://laohu8.com/S/MAPT\">$(MAPT)$</a> mRNA and tau protein in non-human primates. The company indicates that these results may enable monthly or quarterly dosing with uniform CNS distribution. Presentation slides are available on the Arrowhead website.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Arrowhead Pharmaceuticals Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20251208566889) on December 08, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Arrowhead Pharmaceuticals Launches Phase 1/2a Trial of ARO-MAPT for Alzheimer’s Disease</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nArrowhead Pharmaceuticals Launches Phase 1/2a Trial of ARO-MAPT for Alzheimer’s Disease\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-12-08 20:30</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Arrowhead Pharmaceuticals Launches Phase 1/2a Trial of ARO-MAPT for Alzheimer's Disease\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Arrowhead Pharmaceuticals Inc. announced the initiation of a Phase 1/2a clinical trial for ARO-MAPT, an investigational RNA interference (RNAi) therapeutic targeting tauopathies, including Alzheimer's disease. ARO-MAPT utilizes Arrowhead's proprietary Targeted RNAi Molecule (TRiM™) platform, designed for subcutaneous administration and systemic delivery to the central nervous system by crossing the blood-brain barrier. In preclinical studies presented at the RNA Leaders USA Congress 2025, ARO-MAPT demonstrated potent and sustained suppression of microtubule associated protein tau <a href=\"https://laohu8.com/S/MAPT\">$(MAPT)$</a> mRNA and tau protein in non-human primates. The company indicates that these results may enable monthly or quarterly dosing with uniform CNS distribution. Presentation slides are available on the Arrowhead website.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Arrowhead Pharmaceuticals Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20251208566889) on December 08, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4585","symbol_name":"ETF&股票定投概念","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251208:nNDL7mDcF4:1","article_id":"2589330083","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2589330083","pubTimestamp":1765197033,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Arrowhead Pharmaceuticals Inc. announced the initiation of a Phase 1/2a clinical trial for ARO-MAPT, an investigational RNA interference  therapeutic targeting tauopathies, including Alzheimer's disease. ARO-MAPT utilizes Arrowhead's proprietary Targeted RNAi Molecule  platform, designed for subcutaneous administration and systemic delivery to the central nervous system by crossing the blood-brain barrier. In preclinical studies presented at the RNA Leaders USA Congress 2025, ARO-MAPT demonstrated potent and sustained suppression of microtubule associated protein tau  mRNA and tau protein in non-human primates. The company indicates that these results may enable monthly or quarterly dosing with uniform CNS distribution. Presentation slides are available on the Arrowhead website.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informati","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4585":"ETF&股票定投概念","BK4588":"碎股","ARWR":"Arrowhead Research Corporation","BK4139":"生物科技"},"translate_title":"Arrowhead Pharmaceuticals启动ARO-MAPT治疗阿尔茨海默病的1/2期试验","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ARWR":0.9},"content_text":"Arrowhead Pharmaceuticals Launches Phase 1/2a Trial of ARO-MAPT for Alzheimer's Disease\n    \n\n        Arrowhead Pharmaceuticals Inc. announced the initiation of a Phase 1/2a clinical trial for ARO-MAPT, an investigational RNA interference (RNAi) therapeutic targeting tauopathies, including Alzheimer's disease. ARO-MAPT utilizes Arrowhead's proprietary Targeted RNAi Molecule (TRiM™) platform, designed for subcutaneous administration and systemic delivery to the central nervous system by crossing the blood-brain barrier. In preclinical studies presented at the RNA Leaders USA Congress 2025, ARO-MAPT demonstrated potent and sustained suppression of microtubule associated protein tau $(MAPT)$ mRNA and tau protein in non-human primates. The company indicates that these results may enable monthly or quarterly dosing with uniform CNS distribution. Presentation slides are available on the Arrowhead website.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Arrowhead Pharmaceuticals Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20251208566889) on December 08, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}